Search

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Are combination therapies the answer to battling KRAS cancers?

Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal

Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US

Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.

Novel antibody shows potential to transform treatment of rare form of psoriasis

Full results from EMPERIAL exercise ability trials presented

Results for Jardiance® (empaglifozin) | BI US

Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.

Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

Boehringer Ingelheim to unveil oncology research at WCLC

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

U.S. FDA grants Breakthrough Therapy designation for MASH

Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis

We support non-linear career paths.

Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”

Our Curiosity Never Stops | Boehringer Ingelheim US

Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer

Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US

Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.

Results announced from EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial in adults following a heart attack.

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Telemedicine – the standalone study that became the new normal

Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions | Boehringer Ingelheim US

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions

Full data announced in DINAMO trial in young people with T2D

Jardiance (empagliflozin) tablets is the first SGLT2 inhibitor to show statistically significant

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis

Our Partners: ViraTherapeutics

The power of patient advocacy in cancer care

Patients and advocacy organizations agree that patient empowerment is key to quality cancer care

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers